Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in COPD with Elevated IgE
NCT00851370Phase 2Withdrawn
- Sponsor
- National Jewish Health
- Start
- Jan 2009
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in chronic obstructive pulmonary disease (COPD), sponsored by National Jewish Health. Planned start Jan 2009; status: withdrawn.
02
Drugs
omalizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00851370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00851370.